{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:41Z","timestamp":1777934741265,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Clinical Translation Research on Anti-Exhaustion CAR-T Cells, Hefei Natural Science Foundation","award":["HZR2448"],"award-info":[{"award-number":["HZR2448"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the impact of treatment duration on quality of life (QoL), economic burden, and work productivity among chronic myeloid leukemia (CML) survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center cross-sectional design was adopted, and 72 CML survivors who received treatment for \u22653 months were enrolled. Correlation analysis and multivariate linear regression were used to analyze the association between treatment duration and the outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Treatment duration was an independent negative predictor of overall QoL (\u03b2\u2009=\u2009\u22120.013,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and an independent positive predictor of perceived economic burden (\u03b2\u2009=\u20090.023,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and overall work productivity loss rate (\u03b2\u2009=\u20090.302,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Stratified analysis showed that treatment duration was significantly positively correlated with economic burden in low-income patients and those receiving combined therapy or post-transplant maintenance therapy (both\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.008), with total treatment costs mediating 60.9% of this association. Additionally, TKI monotherapy, higher household income, stronger social support, and better physical function were protective factors for QoL, while anxiety and depression were associated with more adverse outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prolonged treatment duration is associated with reduced QoL, increased economic burden, and impaired work productivity in CML survivors, with these associations modulated by socioeconomic status, treatment modality, and mental health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261430662","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:04:09Z","timestamp":1774260249000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of treatment duration on quality of life, economic burden, and work productivity among chronic myeloid leukemia survivors"],"prefix":"10.1177","author":[{"given":"Lingling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, Anhui No.2 Provincial People's Hospital, Hefei City, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasa","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anhui No.2 Provincial People's Hospital, Hefei City, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youwei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anhui No.2 Provincial People's Hospital, Hefei City, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anhui No.2 Provincial People's Hospital, Hefei City, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3545-0341","authenticated-orcid":false,"given":"Linlin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui No.2 Provincial People's Hospital, Hefei City, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.17849\/insm-52-3-1-7.2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2495369"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00967"},{"key":"e_1_3_2_8_2","first-page":"1494","article-title":"Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients","volume":"26","author":"Rivera DR","year":"2020","unstructured":"Rivera DR, et al. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients. J Manag Care Spec Pharm 2020; 26: 1494\u20131504.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31050"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3549-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1838509"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/nop2.1747"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/PRBM.S320126"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018079"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1808"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4184"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.10.1140"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231196130"},{"key":"e_1_3_2_23_2","article-title":"Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission","author":"Flynn KE","unstructured":"Flynn KE, Atallah E. Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission. Haematologica Epub ahead of print 2025. DOI: 10.3324\/haematol.2025.287766.","journal-title":"Haematologica"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261430662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261430662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261430662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:31Z","timestamp":1777689151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261430662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":22,"alternative-id":["10.1177\/10781552261430662"],"URL":"https:\/\/doi.org\/10.1177\/10781552261430662","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"10781552261430662"}}